BioSurfaces
Ashland, US · Founded 2018 · Massachusetts LLC · 1 known investors
Find your way into BioSurfaces
61 people in our graph share verified history with the BioSurfaces team — schools, employers, funds. One of them is your warm intro.
Graham Gardnerunlockedknows Matthew D. Phaneuf · together at Beth Israel Deaconess Medical Center (overlapped)
×9knows the team · via Beth Israel Deaconess Medical Center
×2knows the team · via University of Massachusetts Dartmouth
BioSurfaces develops medical devices, 3D tissue engineering scaffolds, and personal care products using its proprietary Bio-Spun nanofiber technology. The company works in the medical device and tissue engineering space, with collaborations that include Takeda, NIH, and Corning.
Founders & leadership
BioSurfaces was founded in 2018 by Tina M Phaneuf and Matthew D. Phaneuf.
TM
Tina M PhaneufinExecutive Officer and Director of ManagerTina Phaneuf brings 23 years of experience in textile materials research and development, with particular focus on biomedical applications, and has spent the past 13 years managing operations including finance, procurement, and budget oversight at BioSurfaces.
MD
Matthew D. PhaneufinCo-founder · President and CEOMatthew D. Phaneuf is an executive with expertise in biomaterials, tissue engineering, and medical device development. He holds six issued patents in biomaterial synthesis and cell encapsulation, has authored over 30 peer-reviewed publications, and previously secured $6.6 million in federal small business grants to advance platform technology.
Board
TL
Thomas L BarretteDirector of Manager
Investors · 1
Reported raises · per SEC filings
Form D private placements$900K disclosed across 1 round · 2018
▶$900KraisedMar 2018 · 10 investors · BiotechnologyRule 506(b)
▶$900KraisedMar 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tina M PhaneufExecutive Officer, Director
- Matthew D. PhaneufExecutive Officer, Director
- Thomas L BarretteDirector
- Amount sold
- $900K
- Minimum investment
- $25K
- Proceeds to insiders
- $150K
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Massachusetts, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBiomerics9 shared keywordsBiomerics is a vertically integrated contract manufacturer for interventional medical devices, offering engineering, materials, and process expertise through 12 facilities. The company serves original equipment manufacturers in the medical device market with comprehensive design-to-manufacturing capabilities.
Imbed Biosciences8 shared keywordsImbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
Companies competing with BioSurfaces for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 16 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $884.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $275.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $988.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2011 | $749K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $111.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2009 | $110.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2008 | $100K |
| National Science Foundation | Phase ISTTR | 2007 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $744.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2006 | $744.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2005 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $200K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does BioSurfaces do?
- BioSurfaces develops medical devices, 3D tissue engineering scaffolds, and personal care products using its proprietary Bio-Spun nanofiber technology. The company works in the medical device and tissue engineering space, with collaborations that include Takeda, NIH, and Corning.
- Who founded BioSurfaces?
- BioSurfaces was founded by Tina M Phaneuf, Matthew D. Phaneuf in 2018.
- Who are BioSurfaces's investors?
- BioSurfaces's investors include Bill & Melinda Gates Foundation.
- How much funding has BioSurfaces raised?
- BioSurfaces has disclosed $900K raised across 1 round.
- Where is BioSurfaces headquartered?
- BioSurfaces is headquartered in Ashland, US.